Company Name, Ticker, Suppliers, else..

Gelesis Holdings Inc (GLS)

Sector • Healthcare Industry • Major Pharmaceutical Preparations

Industry • Major Pharmaceutical Preparations

Sector • Healthcare

Gelesis Holdings Inc 's

Name: Gelesis Holdings Inc Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Competitiveness

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

GLS Sales vs. its Competitors Q2 2023

Comparing the current results to its competitors, Gelesis Holdings Inc reported Revenue decrease in the 2 quarter 2023 year on year by -87.66 %, despite the revenue increase by the most of its competitors of 22.67 %, recorded in the same quarter.

• List of GLS Competitors

Select the Relationship:

Competition ▼

Select the Category:

Comparison ▼

Competition ▼

Basic Report▼

Revenue Growth Comparisons

Net Income Comparison

Gelesis Holdings Inc , slower than the average decrease reported by the company's competitors of -36.62 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -36.62 %

<< GLS Stock Performance Comparisons

<< See the full list of GLS competitors

Overall company Market Share Q2 2023

Overall company, revenue fell by -87.66 % and company lost market share, to approximately 0.01 %. << More on GLS Market Share.

*Market share is calculated based on total revenue.

GLS's Stock Performance relative to its Competitors

Publicly Traded Peers of Gelesis Holdings Inc

Bellerophon Therapeutics inc
Share Performance

-67.57%

30 Days

Bellerophon Therapeutics inc

Profile

Bellerophon Therapeutics Inc operates under a business model focused on developing and commercializing innovative therapies for cardiopulmonary diseases. They aim to leverage their unique technology platform to advance their product pipeline, ultimately improving patient outcomes and driving sustainable growth in the healthcare market.

More about Bellerophon Therapeutics inc's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 0.147 mill.	$ - mill.	$ -9.253 mill.

Cosciens Biopharma Inc
Share Performance

+36.00%

30 Days

Cosciens Biopharma Inc

Profile

The company develops and commercializes products utilizing PGX Technology.

More about Cosciens Biopharma Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 8.610 mill.	$ 7.498 mill.	$ -10.358 mill.

Diamedica Therapeutics Inc
Share Performance

-1.52%

Over The Past 5 Days

Diamedica Therapeutics Inc

Profile

Diamedica Therapeutics Inc's business model focuses on developing and commercializing innovative therapies to improve patient outcomes in areas of unmet medical needs.

More about Diamedica Therapeutics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 348.157 mill.	$ - mill.	$ -37.541 mill.

Galmed Pharmaceuticals Ltd
Share Performance

+680.78%

30 Days

Galmed Pharmaceuticals Ltd

Profile

Galmed Pharmaceuticals Ltd's business model focuses on the development and commercialization of innovative therapeutic solutions, particularly in the field of liver and metabolic diseases.

More about Galmed Pharmaceuticals Ltd 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 2.495 mill.	$ - mill.	$ 1.400 mill.

Ironwood Pharmaceuticals inc
Share Performance

-7.58%

Over The Past 5 Days

Ironwood Pharmaceuticals inc

Profile

Ironwood Pharmaceuticals Inc is a biotechnology company that focuses on the development and commercialization of medicines for gastrointestinal disorders. Their business model involves discovering, developing, and marketing innovative treatments for conditions like irritable bowel syndrome and chronic constipation. They aim to achieve growth and profitability by leveraging their research capabilities and collaborating with strategic partners in the healthcare industry.

More about Ironwood Pharmaceuticals inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 662.865 mill.	$ 389.316 mill.	$ 129.868 mill.

9 more competitors available

Sources: Gelesis Holdings Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Saturday, September 12, 2026 2:09 PM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Gelesis Holdings Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.